Sarepta science officer Krieg 'terminated' quietly

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Sarepta science officer Krieg 'terminated' quietly

Sarepta Therapeutics ($SRPT) quietly dispensed with Arthur Krieg, whom the company hired just 7 months ago as senior vice president and chief scientific officer. Sarepta filed with the SEC Thursday morning and issued a statement that Krieg had been "terminated." Analysts like Adam Feuerstein indicated that Krieg had been less than stellar for Sarepta in moving programs to the clinic, but they're all rumors at this point. Sarepta slipped in its shares on the news as it looks for approval of its Duchenne muscular dystrophy drug eteplirsen. More | Release

Sarepta Therapeutics
Arthur Krieg was let go from his senior VP and CSO position.


> GliaCure has appointed Joseph Zakrzewski to its board of directors. Release

> Cannabis Science has appointed Roscoe Moore for a second term on its scientific advisory board and as a special senior adviser to the company. Release

> Protalix BioTherapeutics ($PLX) has named Shlomo Yanai as chairman of its board of directors. Release

> Flexion Therapeutics ($FLXN) has appointed Sandesh Mahatme to its board of directors and as chairman of the audit committee of the board. Dr. Rafaéle Tordjman is stepping down from the company's board of directors. Release

> Dale Sander has joined Juventas Therapeutics as the company's chief financial officer, and Dr. Francis Plat as its chief strategy officer. Release

> Sysmex has appointed John Kershaw as an executive officer. Kershaw currently serves as the president and chief executive officer of Sysmex America. Release

> Blueprint Medicines has appointed Jeffrey Albers as its chief executive officer. Release

> Zenith Epigenetics has appointed Julie Cherrington as president and CEO. Release

> David Snyder has joined AuraSense Therapeutics as CFO. Release

> Ultragenyx Pharmaceutical ($RARE) has appointed Dr. Sunil Agarwal as its chief medical officer and senior vice president. Release

> ViaMet Pharmaceuticals has announced the appointment of Amir Tavakkol as its chief development officer. Release


> Bristol-Myers Squibb ($BMY) has appointed Jitendra Tyagi as its India country head. Release

> Clarus Therapeutics has appointed Elizabeth Cermak and Mark Prygocki to its board of directors. Release

Medical Devices

> Alliqua BioMedical ($ALQA) has announced the appointment of Andrew Africk and Gary Restani to its board of directors. Release

> Joseph Corasanti has stepped down as CEO of ConMed ($CNMD). The board has appointed Curt Hartman as its interim CEO. Story

Biotech IT

> Cypher Genomics has named Henry Nordhoff as executive chairman of its board of directors, and also appointed Herbert Boyer and Dr. Andrew von Eschenbach as directors. The company also appointed Adam Simpson as its president and chief operating officer. Release | Release


> Agena Biosciences has hired Peter Dansky as its CEO. Release